["Link: canonical", "Hide glossary", "Glossary", "Study record managers: refer to the Data Element Definitions if submitting", "registration or results information.", "Search for terms", "_____________________ x", "Skip to Main Content", "Working\u2026", "ClinicalTrials.gov", "ClinicalTrials.gov Menu", "* Find StudiesFind Studies Menu", "* New Search", "* Advanced Search", "* See Studies by Topic", "* See Studies on Map", "* How to Search", "* How to Use Search Results", "* How to Find Results of Studies", "* How to Read a Study Record", "* About StudiesAbout Studies Menu", "* Learn About Studies", "* Other Sites About Studies", "* Glossary of Common Site Terms", "* Submit StudiesSubmit Studies Menu", "* Submit Studies to ClinicalTrials.gov PRS", "* Why Should I Register and Submit Results?", "* FDAAA 801 and the Final Rule", "* How to Apply for a PRS Account", "* How to Register Your Study", "* How to Edit Your Study Record", "* How to Submit Your Results", "* Frequently Asked Questions", "* Support Materials", "* Training Materials", "* ResourcesResources Menu", "* Selected Publications", "* Clinical Alerts and Advisories", "* RSS Feeds", "* Trends, Charts, and Maps", "* Downloading Content for Analysis", "* About SiteAbout Site Menu", "* What's New", "* ClinicalTrials.gov Background", "* About the Results Database", "* History, Policies, and Laws", "* ClinicalTrials.gov Modernization", "* Media/Press Resources", "* Linking to This Site", "* Terms and Conditions", "* Disclaimer", "* PRS Login", "* Home", "* Search Results", "* Study Record Detail", "Saved Studies", "[ ] Save this study", "Maximum Saved Studies Reached Warning", "You have reached the maximum number of saved studies (100).", "Please remove one or more studies before adding more.", "[ Close ]", "Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis", "of SARS-CoV-2 Infection (COVID-19)", "The safety and scientific validity of this study is the responsibility of", "the study sponsor and investigators. Listing a study does not mean it has", "been evaluated by the U.S. Federal Government. Read our disclaimer for", "details.", "ClinicalTrials.gov Identifier: NCT04283461", "Recruitment Status : Active, not recruiting", "First Posted : February 25, 2020", "Last Update Posted : March 26, 2021", "Sponsor:", "National Institute of Allergy and Infectious Diseases (NIAID)", "Collaborator:", "ModernaTX, Inc.", "Information provided by (Responsible Party):", "National Institute of Allergy and Infectious Diseases (NIAID)", "* Study Details", "* Tabular View", "* No Results Posted", "* Disclaimer", "* How to Read a Study Record", "Study Description", "Go to  sections", "Top of Page Study Description Study Design Arms and Interventions Outcome", "Measures Eligibility Criteria Contacts and Locations More Information", "Brief Summary:", "This is a phase I, open-label, dose-ranging clinical trial in males and", "non-pregnant females, starting at 18 years of age, inclusive, who are in", "good health and meet all eligibility criteria. This clinical trial is", "designed to assess the safety, reactogenicity and immunogenicity of", "mRNA-1273 manufactured by ModernaTX, Inc. mRNA-1273 is a novel lipid", "nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a", "full-length, prefusion stabilized spike (S) protein of SARS-CoV-2.", "Enrollment will occur at up to 3 domestic clinical research sites. Up to", "one hundred and fifty-five subjects will be enrolled into one of thirteen", "cohorts (10 micrograms [mcg], 25 mcg, 50 mcg, 100 mcg, and 250 mcg).", "Subjects will receive an intramuscular (IM) injection (0.5 milliliters", "[mL]) of mRNA-1273 on Days 1 and 29 in the deltoid muscle and will be", "followed through 12 months post second vaccination (Day 394). Follow-up", "visits will occur 1, 2, and 4 weeks post each vaccination (Days 8, 15, 29,", "36, 43, and 57), as well as 3, 6, and 12 months post second vaccination", "(Days 119, 209, and 394). The primary objective is to evaluate the safety", "and reactogenicity of a 2-dose vaccination schedule of mRNA-1273, given 28", "days apart, across 5 dosages in healthy adults.", "Optional Substudy:", "This is an optional third mRNA-1273 vaccination substudy, in subjects 18", "years of age and older, who received both the first and second mRNA-1273", "vaccinations in the main study and meet all other substudy eligibility", "criteria. This optional third mRNA-1273 vaccination substudy is designed", "to assess safety, reactogenicity, and immunogenicity through 12 months", "post third vaccination (Day 731). Subjects who receive the third mRNA-1273", "vaccination will exit the Schedule of Activities for the main study and", "will enter the Schedule of Activities for the optional substudy. Up to one", "hundred and twenty subject will be enrolled into two cohorts (consisting", "of participating subjects who received 2 doses of 25 or 50 mcg and", "participating subjects who received 2 doses of 100 and 250 mcg). Subjects", "will receive an IM injection (0.5 mL) at a dosage of 100 mcg/0.5 mL. The", "primary objective is to evaluate the safety and reactogenicity of a third", "mRNA-1273 vaccination, at a dosage of 100 mcg.", "+-------------------------------------------------------------------+", "| Condition or disease           | Intervention/treatment | Phase   |", "|--------------------------------+------------------------+---------|", "| COVID-19 COVID-19 Immunisation | Biological: mRNA-1273  | Phase 1 |", "+-------------------------------------------------------------------+", "Detailed Description:", "This is a phase I, open-label, dose-ranging clinical trial in males and", "non-pregnant females, starting at 18 years of age, inclusive, who are in", "good health and meet all eligibility criteria. This clinical trial is", "designed to assess the safety, reactogenicity and immunogenicity of", "mRNA-1273 manufactured by ModernaTX, Inc. mRNA-1273 is a novel lipid", "nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a", "full-length, prefusion stabilized spike (S) protein of SARS-CoV-2.", "Enrollment will occur at up to 3 domestic clinical research sites. Up to", "one hundred and fifty-five subjects will be enrolled into one of thirteen", "cohorts (10 micrograms [mcg], 25 mcg, 50 mcg, 100 mcg, or 250 mcg).", "Subjects will receive an intramuscular (IM) injection (0.5 milliliters", "[mL]) of mRNA-1273 on Days 1 and 29 in the deltoid muscle and will be", "followed through 12 months post second vaccination (Day 394). Follow-up", "visits will occur 1, 2, and 4 weeks post each vaccination (Days 8, 15, 29,", "36, 43, and 57), as well as 3, 6, and 12 months post second vaccination", "(Days 119, 209, and 394). The primary objective is to evaluate the safety", "and reactogenicity of a 2-dose vaccination schedule of mRNA-1273, given 28", "days apart, across 5 dosages in healthy adults. The secondary objective is", "to evaluate the immunogenicity as measured by Immunoglobulin G (IgG)", "enzyme-linked immunosorbent assay (ELISA) to the SARS-CoV-2 S (spike)", "protein following a 2-dose vaccination schedule of mRNA-1273 at Day 57.", "Optional Substudy:", "This is an optional third mRNA-1273 vaccination substudy, in subjects 18", "years of age and older, who received both the first and second mRNA-1273", "vaccinations in the main study and meet all other substudy eligibility", "criteria. This optional third mRNA-1273 vaccination substudy is designed", "to assess safety, reactogenicity, and immunogenicity through 12 months", "post third vaccination (Day 731). Subjects who receive the third mRNA-1273", "vaccination will exit the Schedule of Activities for the main study and", "will enter the Schedule of Activities for the optional substudy. Up to one", "hundred and twenty subject will be enrolled into two cohorts (consisting", "of participating subjects who received 2 doses of 25 or 50 mcg and", "participating subjects who received 2 doses of 100 and 250 mcg). Subjects", "will receive an IM injection (0.5 mL) at a dosage of 100 mcg/0.5 mL. The", "primary objective is to evaluate the safety and reactogenicity of a third", "mRNA-1273 vaccination, at a dosage of 100 mcg. The secondary objective is", "to evaluate the immunogenicity as measured by IgG ELISA to the SARS-CoV-2", "S protein following a third mRNA-1273 vaccination, at a dosage of 100 mcg,", "at all timepoints after the third mRNA-1273 vaccination.", "Study Design", "Go to  sections", "Top of Page Study Description Study Design Arms and Interventions Outcome", "Measures Eligibility Criteria Contacts and Locations More Information", "Layout table for study information", "Study Type :               Interventional  (Clinical Trial)", "Actual Enrollment :        120 participants", "Allocation:                Non-Randomized", "Intervention Model:        Sequential Assignment", "Masking:                   None (Open Label)", "Primary Purpose:           Prevention", "Phase I, Open-Label, Dose-Ranging Study of the", "Official Title:            Safety and Immunogenicity of 2019-nCoV Vaccine", "(mRNA-1273) in Healthy Adults", "Actual Study Start Date :  March 16, 2020", "Estimated Primary          November 22, 2022", "Completion Date :", "Estimated Study Completion November 22, 2022", "Date :", "Arms and Interventions", "Go to  sections", "Top of Page Study Description Study Design Arms and Interventions Outcome", "Measures Eligibility Criteria Contacts and Locations More Information", "Arm                             Intervention/treatment", "Biological: mRNA-1273", "Experimental: Arm 1             Lipid nanoparticle (LNP) dispersion", "25 mcg of mRNA-1273             containing an mRNA that encodes for the", "administered through 0.5 mL     prefusion stabilized spike protein", "intramuscular injection in the  2019-nCoV. mRNA-1273 consists of an mRNA", "deltoid muscle on Days 1 and 29 Drug Substance that is manufactured into", "in participants from 18-55      LNPs composed of the proprietary ionizable", "years of age. N=15 (4 sentinel, lipid, SM-102, and 3 commercially", "11 non-sentinel)                available lipids, cholesterol, DSPC, and", "PEG2000 DMG.", "Biological: mRNA-1273", "Experimental: Arm 10            Lipid nanoparticle (LNP) dispersion", "50 mcg of mRNA-1273             containing an mRNA that encodes for the", "administered through 0.5 mL     prefusion stabilized spike protein", "intramuscular injection in the  2019-nCoV. mRNA-1273 consists of an mRNA", "deltoid muscle on Days 1 and 29 Drug Substance that is manufactured into", "in participants from 18-55      LNPs composed of the proprietary ionizable", "years of age. N=15.             lipid, SM-102, and 3 commercially", "available lipids, cholesterol, DSPC, and", "PEG2000 DMG.", "Biological: mRNA-1273", "Experimental: Arm 11            Lipid nanoparticle (LNP) dispersion", "50 mcg of mRNA-1273             containing an mRNA that encodes for the", "administered through 0.5 mL     prefusion stabilized spike protein", "intramuscular injection in the  2019-nCoV. mRNA-1273 consists of an mRNA", "deltoid muscle on Days 1 and 29 Drug Substance that is manufactured into", "in participants from 56-70      LNPs composed of the proprietary ionizable", "years of age. N=10.             lipid, SM-102, and 3 commercially", "available lipids, cholesterol, DSPC, and", "PEG2000 DMG.", "Biological: mRNA-1273", "Experimental: Arm 12            Lipid nanoparticle (LNP) dispersion", "50 mcg of mRNA-1273             containing an mRNA that encodes for the", "administered through 0.5 mL     prefusion stabilized spike protein", "intramuscular injection in the  2019-nCoV. mRNA-1273 consists of an mRNA", "deltoid muscle on Days 1 and 29 Drug Substance that is manufactured into", "in participants 71 years of age LNPs composed of the proprietary ionizable", "or older. N=10.                 lipid, SM-102, and 3 commercially", "available lipids, cholesterol, DSPC, and", "PEG2000 DMG.", "Biological: mRNA-1273", "Experimental: Arm 13            Lipid nanoparticle (LNP) dispersion", "10 mcg of mRNA-1273             containing an mRNA that encodes for the", "administered through 0.5 mL     prefusion stabilized spike protein", "intramuscular injection in the  2019-nCoV. mRNA-1273 consists of an mRNA", "deltoid muscle on Days 1 and 29 Drug Substance that is manufactured into", "in participants from 18-55      LNPs composed of the proprietary ionizable", "years of age. N=15.             lipid, SM-102, and 3 commercially", "available lipids, cholesterol, DSPC, and", "PEG2000 DMG.", "Experimental: Arm 14            Biological: mRNA-1273", "Optional third mRNA-1273        Lipid nanoparticle (LNP) dispersion", "vaccination sub-study. 100 mcg  containing an mRNA that encodes for the", "of mRNA-1273 administered       prefusion stabilized spike protein", "through 0.5 mL intramuscular    2019-nCoV. mRNA-1273 consists of an mRNA", "injection in the deltoid muscle Drug Substance that is manufactured into", "after Day 209 in participants   LNPs composed of the proprietary ionizable", "from Arm 1,4,7,10, 11, and 12   lipid, SM-102, and 3 commercially", "from 18 years of age or older.  available lipids, cholesterol, DSPC, and", "N=70.                           PEG2000 DMG.", "Experimental: Arm 15            Biological: mRNA-1273", "Optional third mRNA-1273        Lipid nanoparticle (LNP) dispersion", "vaccination sub-study. 100 mcg  containing an mRNA that encodes for the", "of mRNA-1273 administered       prefusion stabilized spike protein", "through 0.5 mL intramuscular    2019-nCoV. mRNA-1273 consists of an mRNA", "injection in the deltoid muscle Drug Substance that is manufactured into", "no later than Day 394 in        LNPs composed of the proprietary ionizable", "participants from Arm 2,3,5 and lipid, SM-102, and 3 commercially", "8 from 18 years of age or       available lipids, cholesterol, DSPC, and", "older. N=50.                    PEG2000 DMG.", "Biological: mRNA-1273", "Experimental: Arm 2             Lipid nanoparticle (LNP) dispersion", "100 mcg of mRNA-1273            containing an mRNA that encodes for the", "administered through 0.5 mL     prefusion stabilized spike protein", "intramuscular injection in the  2019-nCoV. mRNA-1273 consists of an mRNA", "deltoid muscle on Days 1 and 29 Drug Substance that is manufactured into", "in participants from 18-55      LNPs composed of the proprietary ionizable", "years of age. N=15 (4 sentinel, lipid, SM-102, and 3 commercially", "11 non-sentinel).               available lipids, cholesterol, DSPC, and", "PEG2000 DMG.", "Biological: mRNA-1273", "Experimental: Arm 3             Lipid nanoparticle (LNP) dispersion", "250 mcg of mRNA-1273            containing an mRNA that encodes for the", "administered through 0.5 mL     prefusion stabilized spike protein", "intramuscular injection in the  2019-nCoV. mRNA-1273 consists of an mRNA", "deltoid muscle on Days 1 and 29 Drug Substance that is manufactured into", "in participants from 18-55      LNPs composed of the proprietary ionizable", "years of age. N=15 (4 sentinel, lipid, SM-102, and 3 commercially", "11 non-sentinel).               available lipids, cholesterol, DSPC, and", "PEG2000 DMG.", "Biological: mRNA-1273", "Experimental: Arm 4             Lipid nanoparticle (LNP) dispersion", "25 mcg of mRNA-1273             containing an mRNA that encodes for the", "administered through 0.5 mL     prefusion stabilized spike protein", "intramuscular injection in the  2019-nCoV. mRNA-1273 consists of an mRNA", "deltoid muscle on Days 1 and 29 Drug Substance that is manufactured into", "in participants from 56-70      LNPs composed of the proprietary ionizable", "years of age. N=10.             lipid, SM-102, and 3 commercially", "available lipids, cholesterol, DSPC, and", "PEG2000 DMG.", "Biological: mRNA-1273", "Experimental: Arm 5             Lipid nanoparticle (LNP) dispersion", "100 mcg of mRNA-1273            containing an mRNA that encodes for the", "administered through 0.5 mL     prefusion stabilized spike protein", "intramuscular injection in the  2019-nCoV. mRNA-1273 consists of an mRNA", "deltoid muscle on Days 1 and 29 Drug Substance that is manufactured into", "in participants from 56-70      LNPs composed of the proprietary ionizable", "years of age. N=10.             lipid, SM-102, and 3 commercially", "available lipids, cholesterol, DSPC, and", "PEG2000 DMG.", "Biological: mRNA-1273", "Experimental: Arm 6             Lipid nanoparticle (LNP) dispersion", "250 mcg of mRNA-1273            containing an mRNA that encodes for the", "administered through 0.5 mL     prefusion stabilized spike protein", "intramuscular injection in the  2019-nCoV. mRNA-1273 consists of an mRNA", "deltoid muscle on Days 1 and 29 Drug Substance that is manufactured into", "in participants from 56-70      LNPs composed of the proprietary ionizable", "years of age. N=10.             lipid, SM-102, and 3 commercially", "available lipids, cholesterol, DSPC, and", "PEG2000 DMG.", "Biological: mRNA-1273", "Experimental: Arm 7             Lipid nanoparticle (LNP) dispersion", "25 mcg of mRNA-1273             containing an mRNA that encodes for the", "administered through 0.5 mL     prefusion stabilized spike protein", "intramuscular injection in the  2019-nCoV. mRNA-1273 consists of an mRNA", "deltoid muscle on Days 1 and 29 Drug Substance that is manufactured into", "in participants 71 years of age LNPs composed of the proprietary ionizable", "or older. N=10.                 lipid, SM-102, and 3 commercially", "available lipids, cholesterol, DSPC, and", "PEG2000 DMG.", "Biological: mRNA-1273", "Experimental: Arm 8             Lipid nanoparticle (LNP) dispersion", "100 mcg of mRNA-1273            containing an mRNA that encodes for the", "administered through 0.5 mL     prefusion stabilized spike protein", "intramuscular injection in the  2019-nCoV. mRNA-1273 consists of an mRNA", "deltoid muscle on Days 1 and 29 Drug Substance that is manufactured into", "in participants 71 years of age LNPs composed of the proprietary ionizable", "or older. N=10.                 lipid, SM-102, and 3 commercially", "available lipids, cholesterol, DSPC, and", "PEG2000 DMG.", "Biological: mRNA-1273", "Experimental: Arm 9             Lipid nanoparticle (LNP) dispersion", "250 mcg of mRNA-1273            containing an mRNA that encodes for the", "administered through 0.5 mL     prefusion stabilized spike protein", "intramuscular injection in the  2019-nCoV. mRNA-1273 consists of an mRNA", "deltoid muscle on Days 1 and 29 Drug Substance that is manufactured into", "in participants 71 years of age LNPs composed of the proprietary ionizable", "or older. N=10.                 lipid, SM-102, and 3 commercially", "available lipids, cholesterol, DSPC, and", "PEG2000 DMG.", "Outcome Measures", "Go to  sections", "Top of Page Study Description Study Design Arms and Interventions Outcome", "Measures Eligibility Criteria Contacts and Locations More Information", "Primary Outcome Measures :", "1. Frequency of solicited local reactogenicity adverse events (AEs)", "[ Time Frame: Through 7 days post-vaccination ]", "2. Frequency of any medically-attended adverse events (MAAEs)", "[ Time Frame: Day 1 to Day 394 ]", "3. Frequency of any medically-attended adverse events (MAAEs)", "[ Time Frame: Through Day 366 post third vaccination ]", "Optional third mRNA-1273 vaccination sub-study", "4. Frequency of any new-onset chronic medical conditions (NOCMCs)", "[ Time Frame: Day 1 to Day 394 ]", "5. Frequency of any new-onset chronic medical conditions (NOCMCs)", "[ Time Frame: Through Day 366 post third vaccination ]", "Optional third mRNA-1273 vaccination sub-study", "6. Frequency of any serious adverse events (SAEs) [ Time Frame: Day 1 to", "Day 394 ]", "7. Frequency of any serious adverse events (SAEs) [ Time Frame: Through", "Day 366 post third vaccination ]", "Optional third mRNA-1273 vaccination sub-study", "8. Frequency of any unsolicited adverse events (AEs)", "[ Time Frame: Through 28 days post third vaccination ]", "Optional third mRNA-1273 vaccination sub-study", "9. Frequency of any unsolicited adverse events (AEs)", "[ Time Frame: Through 28 days post-vaccination ]", "10. Frequency of solicited local reactogenicity adverse events (AEs)", "[ Time Frame: Through 7 days post third vaccination ]", "Optional third mRNA-1273 vaccination sub-study", "11. Frequency of solicited systemic reactogenicity adverse events (AEs)", "[ Time Frame: Through 7 days post third vaccination ]", "Optional third mRNA-1273 vaccination sub-study", "12. Frequency of solicited systemic reactogenicity adverse events (AEs)", "[ Time Frame: Through 7 days post-vaccination ]", "13. Grade of any unsolicited adverse events (AEs) [ Time Frame: Through 28", "days post third vaccination ]", "Optional third mRNA-1273 vaccination sub-study", "14. Grade of any unsolicited adverse events (AEs) [ Time Frame: Through 28", "days post-vaccination ]", "15. Grade of solicited local reactogenicity adverse events (AEs)", "[ Time Frame: Through 7 days post third vaccination ]", "Optional third mRNA-1273 vaccination sub-study", "16. Grade of solicited local reactogenicity adverse events (AEs)", "[ Time Frame: Through 7 days post-vaccination ]", "17. Grade of solicited systemic reactogenicity adverse events (AEs)", "[ Time Frame: Through 7 days post third vaccination ]", "Optional third mRNA-1273 vaccination sub-study", "18. Grade of solicited systemic reactogenicity adverse events (AEs)", "[ Time Frame: Through 7 days post-vaccination ]", "Secondary Outcome Measures :", "1. Geometric mean fold rise (GMFR) in IgG titer from baseline", "[ Time Frame: Day 1 to Day 57 ]", "2. Geometric mean fold rise (GMFR) in IgG titer from pre-first dose", "baseline [ Time Frame: Day 1 through Day 366 post third vaccination ]", "Optional third mRNA-1273 vaccination sub-study", "3. Geometric mean fold rise (GMFR) in IgG titer from pre-third dose", "baseline [ Time Frame: Through Day 366 post third vaccination ]", "Optional third mRNA-1273 vaccination sub-study", "4. Geometric mean titer (GMT) of antibody [ Time Frame: Day 57 ]", "5. Geometric mean titer (GMT) of antibody [ Time Frame: Through Day 366", "post third vaccination ]", "Optional third mRNA-1273 vaccination sub-study", "6. Percentage of subjects who seroconverted [ Time Frame: Day 1 to Day", "57 ]", "Seroconversion is defined as a 4-fold change in antibody titer from", "baseline", "7. Percentage of subjects who seroconverted from pre-first dose baseline", "[ Time Frame: Day 1 through Day 366 post third vaccination ]", "Optional third mRNA-1273 vaccination sub-study. Seroconversion is", "defined as a 4-fold change in antibody titer", "8. Percentage of subjects who seroconverted from pre-third dose baseline", "[ Time Frame: Through Day 366 post third vaccination ]", "Optional third mRNA-1273 vaccination sub-study. Seroconversion is", "defined as a 4-fold change in antibody titer", "Eligibility Criteria", "Go to  sections", "Top of Page Study Description Study Design Arms and Interventions Outcome", "Measures Eligibility Criteria Contacts and Locations More Information", "Information from the National Library of Medicine", "Choosing to participate in a study is an important personal decision. Talk", "with your doctor and family members or friends about deciding to join a", "study. To learn more about this study, you or your doctor may contact the", "study research staff using the contacts provided below. For general", "information, Learn About Clinical Studies.", "Layout table for eligibility information", "Ages Eligible for Study:      18 Years to 99 Years   (Adult, Older Adult)", "Sexes Eligible for Study:     All", "Accepts Healthy Volunteers:   Yes", "Criteria", "Inclusion Criteria:", "A subject must meet all of the following criteria to be eligible to", "participate in this study:", "1. Provides written informed consent prior to initiation of any study", "procedures.", "2. Be able to understand and agrees to comply with planned study", "procedures and be available for all study visits.", "3. Agrees to the collection of venous blood per protocol.", "4. Male or non-pregnant female, >/= to 18 years of age at time of", "enrollment.", "5. Body Mass Index (BMI) 18.0-35.0 kg/m^2, inclusive (< 56 years of age),", "at screening; BMI 18.0-30.0 kg/m^2, inclusive (>/= 56 years of age),", "at screening.", "6. Women of childbearing potential* must agree to use or have practiced", "true abstinence** or use at least one acceptable primary form of", "contraception.***, **** Note: These criteria are applicable to females", "in a heterosexual relationship and child-bearing potential (i.e., the", "criteria do not apply to subjects in a same sex relationship).", "* Not of childbearing potential - post-menopausal females (defined", "as having a history of amenorrhea for at least one year) or a", "documented status as being surgically sterile (hysterectomy,", "bilateral oophorectomy, tubal ligation/salpingectomy, or", "Essure(R) placement).", "* True abstinence is 100% of time no sexual intercourse", "(male's penis enters the female's vagina). (Periodic", "abstinence [e.g., calendar, ovulation, symptothermal,", "post-ovulation methods] and withdrawal are not acceptable", "methods of contraception).", "* Acceptable forms of primary contraception include", "monogamous relationship with a vasectomized partner who", "has been vasectomized for 180 days or more prior to the", "subject's first vaccination, intrauterine devices,", "birth control pills, and", "injectable/implantable/insertable hormonal birth", "control products.", "* Must use at least one acceptable primary form of", "contraception for at least 30 days prior to the", "first vaccination and at least one acceptable", "primary form of contraception for 60 days after", "the last vaccination.", "7. Women of childbearing potential must have a negative urine or serum", "pregnancy test within 24 hours prior to each vaccination.", "8. Male subjects of childbearing potential*: use of condoms to ensure", "effective contraception with a female partner of childbearing", "potential from first vaccination until 60 days after the last", "vaccination.", "*Biological males who are post-pubertal and considered fertile until", "permanently sterile by bilateral orchiectomy or vasectomy.", "9. Male subjects agree to refrain from sperm donation from the time of", "first vaccination until 60 days after the last vaccination.", "10. In good health.* *As determined by medical history and physical", "examination to evaluate acute or ongoing chronic medical", "diagnoses/conditions that have been present for at least 90 days,", "which would affect the assessment of safety of subjects. Chronic", "medical diagnoses/conditions should be stable for the last 60 days (no", "hospitalizations, emergency room (ER), or urgent care for condition or", "need for supplemental oxygen). This includes no change in chronic", "prescription medication, dose, or frequency as a result of", "deterioration of the chronic medical diagnosis/condition in the 60", "days before enrollment. Any prescription change that is due to change", "of health care provider, insurance company, etc., or done for", "financial reasons, and in the same class of medication, will not be", "considered a deviation of this inclusion criterion. Any change in", "prescription medication due to improvement of a disease outcome, as", "determined by the participating site principal investigator (PI) or", "appropriate sub-investigator, will not be considered a deviation of", "this inclusion criterion. Subjects may be on chronic or as needed", "(prn) medications if, in the opinion of the participating site PI or", "appropriate sub-investigator, they pose no additional risk to subject", "safety or assessment of reactogenicity and immunogenicity, and do not", "indicate a worsening of medical diagnosis/condition. Similarly,", "medication changes subsequent to enrollment and study vaccination are", "acceptable provided the change was not precipitated by deterioration", "in the chronic medical condition, and there is no anticipated", "additional risk to the subject or interference with the evaluation of", "responses to study vaccination.", "11. Oral temperature is less than 100.0 degrees Fahrenheit (37.8 degrees", "Celsius).", "12. Pulse no greater than 100 beats per minute.", "13. Systolic blood pressure (BP) is 85 to 150 mm Hg, inclusive.", "14. Clinical screening laboratory evaluations (white blood cell (WBC),", "hemoglobin (Hgb), platelets (PLTs), alanine transaminase (ALT),", "aspartate transaminase (AST), creatinine (Cr), alkaline phosphatase", "(ALP), total bilirubin (T. Bili), Lipase, prothrombin time (PT), and", "partial thromboplastin time (PTT)) are within acceptable normal", "reference ranges at the clinical laboratory being used.", "15. Must agree to have samples stored for secondary research.", "16. Agrees to adhere to Lifestyle Considerations throughout study", "duration.", "17. Must agree to refrain from donating blood or plasma during the study", "(outside of this study).", "Leukapheresis Inclusion Criteria:", "A subject must meet all of the following criteria to be eligible for", "leukapheresis:", "1. Written informed consent for leukapheresis is provided.", "2. Weight >/= 110 pounds.", "3. Screening laboratory evaluations are within acceptable ranges at the", "site where the leukapheresis procedure will be performed.", "4. Negative urine or serum pregnancy test within 48 hours of the", "leukapheresis procedure for women of childbearing potential.", "5. Adequate bilateral antecubital venous access.", "6. No use of blood thinners, aspirin or nonsteroidal anti-inflammatory", "drugs (NSAIDs) at least 5 days before the leukapheresis procedure.", "7. Enrolled in cohorts 2, 3, 5, 10, or 11, and possibly cohort 6, if", "enrolled, and completed the two-dose vaccination series.", "Optional Substudy Inclusion Criteria:", "1. Enrolled in the main study and received both the first and second", "mRNA-1273 vaccinations.", "2. Provides written informed consent for the third mRNA-1273 vaccination.", "3. Agrees to the collection of venous blood per substudy.", "4. Must agree to have samples stored for secondary research.", "5. Women of childbearing potential have had a negative urine pregnancy", "test within 24 hours before the third mRNA-1273 vaccination.", "6. Women of childbearing potential* must agree to use or have practiced", "true abstinence** or use at least one acceptable primary form of", "contraception.***/****", "* Not of childbearing potential - post-menopausal females (defined", "as having a history of amenorrhea for at least one year) or a", "documented status as being surgically sterile (hysterectomy,", "bilateral oophorectomy, tubal ligation/salpingectomy, or Essure\u00ae", "placement).", "* True abstinence is 100% of time no sexual intercourse", "(male's penis enters the female's vagina). (Periodic", "abstinence [e.g., calendar, ovulation, symptothermal,", "post-ovulation methods] and withdrawal are not acceptable", "methods of contraception).", "* Acceptable forms of primary contraception include", "monogamous relationship with a vasectomized partner who", "has been vasectomized for 180 days or more prior to the", "subject's first vaccination, intrauterine devices,", "birth control pills, and", "injectable/implantable/insertable hormonal birth", "control products.", "****Must use at least one acceptable primary form of", "contraception for at least 30 days prior to the third", "mRNA-1273 vaccination and for at least 30 days after", "the third mRNA-1273 vaccination.", "Exclusion Criteria:", "A subject who meets any of the following criteria will be excluded from", "participation in this study:", "1. Positive pregnancy test either at screening or just prior to each", "vaccine administration.", "2. Female subject who is breastfeeding or plans to breastfeed from the", "time of the first vaccination through 60 days after the last", "vaccination.", "3. Has any medical disease or condition that, in the opinion of the", "participating site principal investigator (PI) or appropriate", "sub-investigator, precludes study participation.*", "*Including acute, subacute, intermittent or chronic medical disease or", "condition that would place the subject at an unacceptable risk of", "injury, render the subject unable to meet the requirements of the", "protocol, or may interfere with the evaluation of responses or the", "subject's successful completion of this trial.", "4. Presence of self-reported or medically documented significant medical", "or psychiatric condition(s).*", "*Significant medical or psychiatric conditions include but are not", "limited to: Respiratory disease (e.g., chronic obstructive pulmonary", "disease [COPD], asthma) requiring daily medications currently or any", "treatment of respiratory disease exacerbations (e.g., asthma", "exacerbation) in the last 5 years. Asthma medications: inhaled, oral,", "or intravenous (IV) corticosteroids, leukotriene modifiers, long and", "short acting beta agonists, theophylline, ipratropium, biologics.", "Significant cardiovascular disease (e.g., congestive heart failure,", "cardiomyopathy, ischemic heart disease), history of myocarditis or", "pericarditis as an adult, myocardial infarction (MI) within past 6", "months, coronary artery bypass surgery or stent placement, or", "uncontrolled cardiac arrhythmia.", "Neurological or neurodevelopmental conditions (e.g., history of", "migraines in the past 5 years, epilepsy, stroke, seizures in the last", "3 years, encephalopathy, focal neurologic deficits, Guillain-Barr\u00e9", "syndrome, encephalomyelitis, transverse myelitis, stroke or transient", "ischemic attack, multiple sclerosis, Parkinson's disease, amyotrophic", "lateral sclerosis, Creutzfeldt-Jakob disease, or Alzheimer's disease).", "Ongoing malignancy or recent diagnosis of malignancy in the last five", "years excluding basal cell and squamous cell carcinoma of the skin,", "which are allowed.", "An autoimmune disease, including hypothyroidism without a defined", "non-autoimmune cause, localized or history of psoriasis.", "An immunodeficiency of any cause. Chronic kidney disease, estimated", "glomerular filtration rate (eGFR) <60 mL/min/1.73m^2.", "5. Has an acute illness*, as determined by the participating site PI or", "appropriate sub-investigator, with or without fever [oral temperature", ">/= 38.0 degrees Celsius (100.4 degrees Fahrenheit)] within 72 hours", "prior to each vaccination.", "*An acute illness which is nearly resolved with only minor residual", "symptoms remaining is allowable if, in the opinion of the", "participating site PI or appropriate sub-investigator, the residual", "symptoms will not interfere with the ability to assess safety", "parameters as required by the protocol.", "6. Has a positive test result for hepatitis B surface antigen, hepatitis", "C virus antibody, or human immunodeficiency virus (HIV) types 1 or 2", "antibodies at screening.", "7. Has participated in another investigational study involving any", "investigational product* within 60 days, or 5 half-lives, whichever is", "longer, before the first vaccine administration.", "*study drug, biologic or device", "8. Currently enrolled in or plans to participate in another clinical", "trial with an investigational agent* that will be received during the", "study-reporting period.**", "*Including licensed or unlicensed vaccine, drug, biologic, device,", "blood product, or medication.", "**13 months after the first vaccination.", "9. Has previously participated in an investigational study involving", "lipid nanoparticles (LNPs) (a component of the investigational vaccine", "assessed in this trial).", "10. Has a history of hypersensitivity or severe allergic reaction (e.g.,", "anaphylaxis, generalized urticaria, angioedema, other significant", "reaction) to any previous licensed or unlicensed vaccines.", "11. Chronic use (more than 14 continuous days) of any medications that may", "be associated with impaired immune responsiveness.*", "*Including, but not limited to, systemic corticosteroids exceeding 10", "mg/day of prednisone equivalent, allergy injections, immunoglobulin,", "interferon, immunomodulators, cytotoxic drugs, or other similar or", "toxic drugs during the preceding 6-month period prior to vaccine", "administration (Day 1). The use of low dose topical, ophthalmic,", "inhaled and intranasal steroid preparations will be permitted.", "12. Anticipating the need for immunosuppressive treatment within the next", "6 months.", "13. Received immunoglobulins and/or any blood or blood products within the", "4 months before the first vaccine administration or at any time during", "the study.", "14. Has any blood dyscrasias or significant disorder of coagulation.", "15. Has any chronic liver disease, including fatty liver.", "16. Has a history of alcohol abuse or other recreational drug (excluding", "cannabis) use within 6 months before the first vaccine administration.", "17. Has a positive test result for drugs of abuse at screening or before", "the first vaccine administration. If cannabis is the only detected", "drug, inclusion is permitted.", "18. Has any abnormality or permanent body art (e.g., tattoo) that would", "interfere with the ability to observe local reactions at the injection", "site (deltoid region).", "19. Received or plans to receive a licensed, live vaccine within 4 weeks", "before or after each vaccination.", "20. Received or plans to receive a licensed, inactivated vaccine within 2", "weeks before or after each vaccination.", "21. Receipt of any other SARS-CoV-2 or other experimental coronavirus", "vaccine at any time prior to or during the study.", "22. Close contact of anyone known to have SARS-CoV-2 infection within 30", "days prior to vaccine administration.", "23. History of COVID-19 diagnosis.", "24. On current treatment with investigational agents for prophylaxis of", "COVID-19.", "25. Current use of any prescription or over-the-counter medications within", "7 days prior to vaccination, unless approved by the investigator or", "necessary to manage a chronic condition.", "26. Plan to travel outside the United States (US) (continental US, Hawaii,", "and Alaska) from enrollment through 28 days after the last", "vaccination.", "27. Reside in a nursing home or other skilled nursing facility or have a", "requirement for skilled nursing care.", "28. Non-ambulatory.", "29. For subjects >/= 56 years of age, history of chronic smoking within", "the prior year.", "30. For subjects >/= 56 years of age, current smoking or vaping.", "31. For subjects >/= 56 years of age, individuals currently working with", "high risk of exposure to SARS-CoV-2 (e.g., active health care workers", "with direct patient contact, emergency response personnel).", "Optional Substudy Exclusion Criteria:", "1. Anaphylaxis or other systemic hypersensitivity reaction following a", "mRNA-1273 or any other vaccination.", "2. Immediate allergic reaction of any severity after mRNA-1273 or any of", "its components.*", "*Including polyethylene glycol (PEG)", "3. Immediate allergic reaction of any severity to polysorbate.*", "*Due to potential cross-reactive hypersensitivity with the vaccine", "ingredient PEG", "4. History of an SAE judged related to mRNA-1273 vaccine.", "5. Female subject who is breastfeeding or plans to breastfeed from the", "time of the third mRNA-1273 vaccination through 30 days after the", "third mRNA-1273 vaccination.", "6. Has an acute illness*, as determined by the participating site PI or", "appropriate sub-investigator, with or without fever [oral temperature", ">/=38.0\u00b0C (100.4\u00b0F)], within 72 hours prior to the third mRNA-1273", "vaccination.", "*An acute illness which is nearly resolved with only minor residual", "symptoms remaining is allowable if, in the opinion of the", "participating site PI or appropriate sub-investigator, the residual", "symptoms will not interfere with the ability to assess safety", "parameters as required by the substudy.", "7. Has received any approved, authorized or investigational COVID-19", "vaccine outside of this trial.", "8. Any clinically significant medical condition that, in the opinion of", "the investigator, poses an additional risk to the subject from", "vaccination.", "9. History of documented COVID-19 infection.", "10. Has any medical disease or condition that, in the opinion of the", "participating site PI or appropriate sub-investigator, precludes", "substudy participation.", "11. Received or plans to receive a licensed vaccine, other than a COVID-19", "vaccine, within 2 weeks before or after the third mRNA-1273", "vaccination.", "Contacts and Locations", "Go to  sections", "Top of Page Study Description Study Design Arms and Interventions Outcome", "Measures Eligibility Criteria Contacts and Locations More Information", "Information from the National Library of Medicine", "To learn more about this study, you or your doctor may contact the study", "research staff using the contact information provided by the sponsor.", "Please refer to this study by its ClinicalTrials.gov identifier (NCT", "number): NCT04283461", "Locations", "Layout table for location information", "United States, Georgia", "Emory Vaccine Center - The Hope Clinic", "Decatur, Georgia, United States, 30030-1705", "United States, Maryland", "National Institutes of Health - Clinical Center - Vaccine Research Center", "Clinical Trials Program", "Bethesda, Maryland, United States, 20892", "United States, Washington", "Kaiser Permanente Washington Health Research Institute - Vaccines and", "Infectious Diseases", "Seattle, Washington, United States, 98101-1466", "Sponsors and Collaborators", "National Institute of Allergy and Infectious Diseases (NIAID)", "ModernaTX, Inc.", "More Information", "Go to  sections", "Top of Page Study Description Study Design Arms and Interventions Outcome", "Measures Eligibility Criteria Contacts and Locations More Information", "Publications automatically indexed to this study by ClinicalTrials.gov", "Identifier (NCT Number):", "Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M,", "Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B,", "Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, Corbett KS, Swanson PA 2nd,", "Padilla M, Neuzil KM, Bennett H, Leav B, Makowski M, Albert J, Cross K,", "Edara VV, Floyd K, Suthar MS, Martinez DR, Baric R, Buchanan W, Luke CJ,", "Phadke VK, Rostad CA, Ledgerwood JE, Graham BS, Beigel JH; mRNA-1273 Study", "Group. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older", "Adults. N Engl J Med. 2020 Dec 17;383(25):2427-2438. doi:", "10.1056/NEJMoa2028436. Epub 2020 Sep 29.", "Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN,", "McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ,", "McDermott A, Flach B, Doria-Rose NA, Corbett KS, Morabito KM, O'Dell S,", "Schmidt SD, Swanson PA 2nd, Padilla M, Mascola JR, Neuzil KM, Bennett H,", "Sun W, Peters E, Makowski M, Albert J, Cross K, Buchanan W,", "Pikaart-Tautges R, Ledgerwood JE, Graham BS, Beigel JH; mRNA-1273 Study", "Group. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J", "Med. 2020 Nov 12;383(20):1920-1931. doi: 10.1056/NEJMoa2022483. Epub 2020", "Jul 14.", "Layout table for additonal information", "Responsible Party:             National Institute of Allergy and", "Infectious Diseases (NIAID)", "ClinicalTrials.gov Identifier: NCT04283461", "Other Study ID Numbers:        20-0003", "5UM1AI148684-02 ( U.S. NIH Grant/Contract )", "First Posted:                  February 25, 2020    Key Record Dates", "Last Update Posted:            March 26, 2021", "Last Verified:                 February 9, 2021", "Layout table for additional information", "Studies a U.S. FDA-regulated Drug Product:          Yes", "Studies a U.S. FDA-regulated Device Product:        No", "Product Manufactured in and Exported from the U.S.: No", "Keywords provided by National Institute of Allergy and Infectious Diseases", "(NIAID):", "2019-nCoV (mRNA-1273) novel coronavirus", "COVID-19              Safety", "Dose-escalation       SARS-CoV-2", "Immunogenicity        vaccine", "To Top", "* For Patients and Families", "* For Researchers", "* For Study Record Managers", "* Home", "* RSS Feeds", "* Site Map", "* Terms and Conditions", "* Disclaimer", "* Customer Support", "* Copyright", "* Privacy", "* Accessibility", "* Viewers and Players", "* Freedom of Information Act", "* USA.gov", "* U.S. National Library of Medicine", "* U.S. National Institutes of Health", "* U.S. Department of Health and Human Services"]